In human patients, Akkermansia levels positively correlated with partial response or stable disease, and in mouse models, repletion of Akkermansia via oral gavage was able to repotentiate tumor response to CTLA-4 and PD-L1 therapy [20]. The gene discussed is CTLA4; the disease is neoplasm.